Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
18 results
Cited 2 times since 2020 (0.5 per year) source: EuropePMC
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, Volume 46, Issue 6, 29 5 2020, Pages 1167-1173 Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. Breugom AJ, Bastiaannet E, Guren MG, Kørner H, Boelens PG, Dekker FW, Kapiteijn E, Gelderblom H, Larsen IK, Liefers GJ, van de Velde CJH
Background: The potential benefit of surgery of the primary tumour in patients with asymptomatic metastatic colorectal cancer is debated. This EURECCA international comparison analyses treatment strategies and overall survival in the Netherlands and Norway in patients with incurable metastatic colorectal cancer. Methods: National cohorts (2007-2013) from the Netherlands and Norway including all patients with synchronous metastatic colorectal cancer were compared on treatment strategy and overall... Abstract
Cited 4 times since 2018 (0.7 per year) source: EuropePMC
The Cochrane database of systematic reviews, Volume 11, 21 3 2018, Pages CD012326 Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Claassen YH, van der Valk MJ, Breugom AJ, Frouws MA, Bastiaannet E, Liefers GJ, van de Velde CJ, Kapiteijn E
Background: For patients with asymptomatic, incurable, metastatic colorectal cancer, palliative, systemic treatment can be started immediately, or can be delayed until disease-related symptoms occur. How the potential survival benefit of starting palliative, systemic treatment immediately after diagnosis weighs up against the potential side effects is currently under debate, and was investigated in this review. Objectives: To assess the effects of immediate versus delayed chemotherapy, with or w... Abstract
Cited 17 times since 2018 (3 per year) source: EuropePMC
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, Volume 44, Issue 12, 8 2 2018, Pages 1894-1900 Comprehensive multidisciplinary care program for elderly colorectal cancer patients: "From prehabilitation to independence". Souwer ETD, Bastiaannet E, de Bruijn S, Breugom AJ, van den Bos F, Portielje JEA, Dekker JWT
Background: We implemented a multidisciplinary pre- and rehabilitation program for elderly patients (≥75 years of age) in a single center consisting of prehabilitation, laparoscopic surgery and early rehabilitation with the intention to lower 1-year overall mortality. Methods: In this study we compared all patients that underwent elective surgery for stage I-III colorectal cancer before and during development and after implementation of the program (2010-2011, 2012-2013 and 2014-2015). Primary e... Abstract
Cited 6 times since 2018 (1 per year) source: EuropePMC
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, Volume 44, Issue 12, 29 5 2018, Pages 1889-1893 Decrease in 30-day and one-year mortality over time in patients aged ≥75 years with stage I-III colon cancer: A population-based study. Breugom AJ, Bastiaannet E, Dekker JWT, Wouters MWJM, van de Velde CJH, Liefers GJ
Background: Monitoring time trends of cancer mortality is essential. Thirty-day mortality is an important surgical outcome measure, though postoperative mortality exceeds to one year after surgery in patients with colorectal cancer. The aim of this nationwide observational study was to assess changes over time in 30-day and one-year mortality in patients with stage I-III colorectal cancer. Methods: All surgically treated patients with stage I-III colorectal cancer, diagnosed between 2009 and 201... Abstract
Cited 2 times since 2018 (0.3 per year) source: EuropePMC
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, Volume 44, Issue 9, 26 4 2018, Pages 1338-1343 Oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania. Breugom AJ, Bastiaannet E, Boelens PG, Van Eycken E, Iversen LH, Martling A, Johansson R, Evans T, Lawton S, O'Brien KM, Ortiz H, Janciauskiene R, Dekkers OM, Rutten HJT, Liefers GJ, Lemmens VEPP, van de Velde CJH
Introduction: The aim of this EURECCA international comparison is to compare oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer between European countries. Material and methods: Population-based national cohort data from the Netherlands (NL), Belgium (BE), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), Spain (ES), and single-centre data from Lithuania (LT) were obtained. All operated patients with (y)pTNM stage I-III rectal cancer diagnosed b... Abstract
Cited 4 times since 2017 (0.6 per year) source: EuropePMC
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, Volume 19, Issue 10, 1 1 2017, Pages O358-O364 Administration of adjuvant chemotherapy in older patients with Stage III colon cancer: an observational study. van den Broek CBM, Puylaert CCEM, Breugom AJ, Bastiaannet E, de Craen AJM, van de Velde CJH, Liefers GJ, Portielje JEA
Aim: According to established guidelines, patients with Stage III colon cancer should receive adjuvant chemotherapy. However, a significant proportion do not. This study assessed factors associated with the administration of adjuvant chemotherapy and causes of death. Methods: Patients with Stage III colon cancer who underwent surgery between 2000 and 2009 were selected from two hospitals in the Netherlands. Patient characteristics including comorbidities and treatment preferences, tumour charact... Abstract
Cited 3 times since 2017 (0.4 per year) source: EuropePMC
Annals of oncology : official journal of the European Society for Medical Oncology, Volume 28, Issue 3, 1 1 2017, Pages 664-665 Should rectal cancer located 10-15 cm from the anal verge be defined as colon cancer. Swets M, Breugom AJ, Gelderblom H, van de Velde CJH
Cited 48 times since 2016 (6.2 per year) source: EuropePMC
International journal of colorectal disease, Volume 31, Issue 10, 6 1 2016, Pages 1683-1691 Differences between colon and rectal cancer in complications, short-term survival and recurrences. van der Sijp MP, Bastiaannet E, Mesker WE, van der Geest LG, Breugom AJ, Steup WH, Marinelli AW, Tseng LN, Tollenaar RA, van de Velde CJ, Dekker JW
Purpose: Many apparent differences exist in aetiology, genetics, anatomy and treatment response between colon cancer (CC) and rectal cancer (RC). This study examines the differences in patient characteristics, prevalence of complications and their effect on short-term survival, long-term survival and the rate of recurrence between RC and CC. Methods: For all stage II-III CC and RC patients who underwent resection with curative intent (2006-2008) in five hospitals in the Netherlands, occurrence o... Abstract
Cited 15 times since 2016 (1.9 per year) source: EuropePMC
European journal of cancer (Oxford, England : 1990), Volume 63, 11 2 2016, Pages 110-117 Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. Breugom AJ, Bastiaannet E, Boelens PG, Iversen LH, Martling A, Johansson R, Evans T, Lawton S, O'Brien KM, Van Eycken E, Janciauskiene R, Liefers GJ, Cervantes A, Lemmens VE, van de Velde CJ
Background: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. Methods: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportio... Abstract
Cited 10 times since 2016 (1.2 per year) source: EuropePMC
Annals of surgical oncology, Volume 23, Issue 9, 13 2 2016, Pages 2858-2865 Association Between the Most Frequent Complications After Surgery for Stage I-III Colon Cancer and Short-Term Survival, Long-Term Survival, and Recurrences. Breugom AJ, van Dongen DT, Bastiaannet E, Dekker FW, van der Geest LG, Liefers GJ, Marinelli AW, Mesker WE, Portielje JE, Steup WH, Tseng LN, van de Velde CJ, Dekker JW
Background: The purpose of this study was to identify the ten most frequent complications after surgery for stage I-III colon cancer and to assess the association between these complications and overall survival, conditional overall survival, and recurrences. Methods: All patients who underwent surgery for stage I-III colon cancer in five hospitals in the Western region of the Netherlands were identified. Crude and adjusted Cox proportional hazards models were used to study the association betwe... Abstract
Cited 4 times since 2015 (0.5 per year) source: EuropePMC
The Lancet. Oncology, Volume 16, Issue 8, 5 1 2015, Pages 875-876 Is it time for watchful waiting for rectal cancer? Breugom AJ, van de Velde CJ
Cited 3 times since 2015 (0.3 per year) source: EuropePMC
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, Volume 41, Issue 8, 21 3 2015, Pages 1039-1044 Effect of preoperative treatment strategies on the outcome of patients with clinical T3, non-metastasized rectal cancer: A comparison between Dutch and Canadian expert centers. Breugom AJ, Vermeer TA, van den Broek CB, Vuong T, Bastiaannet E, Azoulay L, Dekkers OM, Niazi T, van den Berg HA, Rutten HJ, van de Velde CJ
Aim: High-dose-rate brachytherapy (HDRBT) appears to be associated with less treatment-related toxicity compared with external beam radiotherapy in patients with rectal cancer. The present study compared the effect of preoperative treatment strategies on overall survival, cancer-specific deaths, and local recurrences between a Dutch and Canadian expert center with different preoperative treatment strategies. Patients and methods: We included 145 Dutch and 141 Canadian patients with cT3, non-meta... Abstract
Cited 1 times since 2015 (0.1 per year) source: EuropePMC
The Lancet. Oncology, Volume 16, Issue 4, 1 1 2015, Pages e155 Adjuvant chemotherapy for rectal cancer - authors' reply. Breugom AJ, Swets M, van de Velde CJ
Cited 239 times since 2015 (25.5 per year) source: EuropePMC
The Lancet. Oncology, Volume 16, Issue 2, 12 2 2015, Pages 200-207 Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, Liefers GJ, Putter H, van de Velde CJ
Background: The role of adjuvant chemotherapy for patients with rectal cancer after preoperative (chemo)radiotherapy and surgery is uncertain. We did a meta-analysis of individual patient data to compare adjuvant chemotherapy with observation for patients with rectal cancer. Methods: We searched PubMed, Medline, Embase, Web of Science, the Cochrane Library, CENTRAL, and conference abstracts to identify European randomised, controlled, phase 3 trials comparing observation with adjuvant chemothera... Abstract
Cited 164 times since 2014 (17.3 per year) source: EuropePMC
Annals of oncology : official journal of the European Society for Medical Oncology, Volume 26, Issue 4, 5 1 2014, Pages 696-701 Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Breugom AJ, van Gijn W, Muller EW, Berglund Å, van den Broek CBM, Fokstuen T, Gelderblom H, Kapiteijn E, Leer JWH, Marijnen CAM, Martijn H, Meershoek-Klein Kranenbarg E, Nagtegaal ID, Påhlman L, Punt CJA, Putter H, Roodvoets AGH, Rutten HJT, Steup WH, Glimelius B, van de Velde CJH
Background: The discussion on the role of adjuvant chemotherapy for rectal cancer patients treated according to current guidelines is still ongoing. A multicentre, randomized phase III trial, PROCTOR-SCRIPT, was conducted to compare adjuvant chemotherapy with observation for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision (TME). Patients and methods: The PROCTOR-SCRIPT trial recruited patients from 52 hospitals. Patients with histologically prov... Abstract
Cited 1 times since 2014 (0.1 per year) source: EuropePMC
The Lancet. Oncology, Volume 15, Issue 11, 4 1 2014, Pages 1185-1186 Adjuvant chemotherapy for patients with rectal cancer? Breugom AJ, van de Velde CJ
Cited 26 times since 2014 (2.6 per year) source: EuropePMC
Annals of oncology : official journal of the European Society for Medical Oncology, Volume 25, Issue 8, 26 4 2014, Pages 1485-1492 Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Breugom AJ, Boelens PG, van den Broek CB, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJ
Colorectal cancer is one of the most common cancers in Europe. Over the past few decades, important advances have been made in screening, staging and treatment of colorectal cancer. However, considerable variation between and within European countries remains, which implies that further improvements are possible. The most important remaining question now is: when are we, health care professionals, delivering the best available care to patients with colon or rectal cancer? Currently, quality assu... Abstract
Cited 25 times since 2013 (2.4 per year) source: EuropePMC
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, Volume 40, Issue 4, 8 2 2013, Pages 454-468 Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. van de Velde CJ, Boelens PG, Tanis PJ, Espin E, Mroczkowski P, Naredi P, Pahlman L, Ortiz H, Rutten HJ, Breugom AJ, Smith JJ, Wibe A, Wiggers T, Valentini V
The first multidisciplinary consensus conference on colon and rectal cancer was held in December 2012, achieving a majority of consensus for diagnostic and treatment decisions using the Delphi Method. This article will give a critical appraisal of the topics discussed during the meeting and in the consensus document by well-known leaders in surgery that were involved in this multidisciplinary consensus process. Scientific evidence, experience and opinions are collected to support multidisciplina... Abstract